{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:00:36Z","timestamp":1792684836693,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK56338"],"award-info":[{"award-number":["P30 DK56338"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220119"],"award-info":[{"award-number":["RP220119"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP150587"],"award-info":[{"award-number":["RP150587"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.01.018","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:44Z","timestamp":1782992204000},"page":"656-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The changing epidemiology of primary liver cancer in the 21st century"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-0911","authenticated-orcid":false,"given":"Shahid A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-4385","authenticated-orcid":false,"given":"Mathew","family":"Vithayathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry C.F.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-7579","authenticated-orcid":false,"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.01.018_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2026.01.018_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib3","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i23.107100","article-title":"Hepatocellular carcinoma in patients without cirrhosis","volume":"31","author":"Sato-Espinoza","year":"2025","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.01.018_bib4","article-title":"Mapping the landscape of biliary tract cancer in Europe: challenges and controversies","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Heal Eur"},{"key":"10.1016\/j.jhep.2026.01.018_bib5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(25)01917-8","article-title":"Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2026.01.018_bib6","unstructured":"International Agency for Research on Cancer. WHO cancer mortality database, world health organization, health statistics and information systems 2019. http:\/\/www-dep.iarc.fr\/WHOdb\/WHOdb.htm (accessed July 24, 2025)."},{"key":"10.1016\/j.jhep.2026.01.018_bib7","first-page":"1","article-title":"Age standardization of rates: a new WHO standard","volume":"31","author":"Ahmad","year":"2001","journal-title":"GPE Discuss Pap Ser"},{"key":"10.1016\/j.jhep.2026.01.018_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","article-title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial","volume":"10","author":"Lim","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2024.11.018","article-title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","volume":"82","author":"Lai","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib10","article-title":"Cost-effectiveness of antiviral therapy in patients with high viremic indeterminate phase chronic hepatitis B","volume":"45","author":"Jang","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.01.018_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.01.018_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(25)00069-X","article-title":"A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles","volume":"10","author":"Hiebert-Suwondo","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib13","unstructured":"World Health Organization (WHO). Hepatitis B vaccination coverage n.d. https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/hepatitis-b-vaccination-coverage?CODE=Global&ANTIGEN=HEPB_BD&YEAR= (accessed December 17, 2025)."},{"key":"10.1016\/j.jhep.2026.01.018_bib14","series-title":"Global hepatitis report 2024","year":"2024"},{"key":"10.1016\/j.jhep.2026.01.018_bib15","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/apt.18525","article-title":"Risk of hepatocellular cancer in U.S. Patients with compensated cirrhosis treated with direct-acting antivirals versus interferon","volume":"61","author":"El-Serag","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.01.018_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jhep.2025.02.008","article-title":"Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis","volume":"83","author":"Nahon","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jhep.2024.09.038","article-title":"Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection","volume":"82","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.01.018_bib19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.744512","article-title":"Diabetes mellitus increases the risk of hepatocellular carcinoma after direct-acting antiviral therapy: systematic review and meta-analysis","volume":"8","author":"V\u00e1ncsa","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jhep.2026.01.018_bib21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3350\/cmh.2024.0835","article-title":"Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021","volume":"31","author":"Danpanichkul","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70053","article-title":"Global, regional and national burden of chronic hepatitis C, 1990-2021: a systematic analysis for the GBD study 2021","volume":"32","author":"Li","year":"2025","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2026.01.018_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30024","article-title":"Hepatitis C virus reinfection among people who inject drugs: long-term follow-up of the HERO study","volume":"7","author":"Litwin","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2026.01.018_bib25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/cid\/ciac246","article-title":"Hepatitis C virus reinfection following direct-acting antiviral treatment in the prison setting: the SToP-C study","volume":"75","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2026.01.018_bib26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/jvh.13378","article-title":"Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH)","volume":"27","author":"Mora","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2026.01.018_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","article-title":"EASL position paper on clinical follow-up after HCV cure","volume":"81","author":"Reiberger","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1186\/s12913-025-12737-2","article-title":"A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol","volume":"25","author":"Godwin","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jhep.2026.01.018_bib31","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2026.01.018_bib32","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s10620-024-08437-2","article-title":"An electronic health record model for predicting risk of hepatic fibrosis in primary care patients","volume":"69","author":"Thrift","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.01.018_bib33","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1016\/j.cgh.2023.04.019","article-title":"Risk stratification model for hepatocellular cancer in patients with cirrhosis","volume":"21","author":"Kanwal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-332034","article-title":"Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis","author":"El-Serag","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.01.018_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-334981","article-title":"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","author":"Lai","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.01.018_bib36","article-title":"Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease","author":"John","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.01.018_bib37","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cgh.2023.03.029","article-title":"Prevention of hepatocellular carcinoma (HCC). White paper of the Texas collaborative center for hepatocellular cancer (TeCH) multi-stakeholder conference","volume":"21","author":"El-Serag","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib38","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2468-2667(25)00174-4","article-title":"National, regional, and global statistics on alcohol consumption and associated burden of disease 2000-20: a modelling study and comparative risk assessment","volume":"10","author":"Shield","year":"2025","journal-title":"Lancet Public Heal"},{"key":"10.1016\/j.jhep.2026.01.018_bib39","unstructured":"World Health Organization (WHO). WHO. Global status report on alcohol and health and treatment of substance use disorders. n.d. https:\/\/www.who.int\/publications\/i\/item\/9789240096745. (accessed November 3, 2025)."},{"key":"10.1016\/j.jhep.2026.01.018_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMra2306511","article-title":"Identification and treatment of alcohol use disorder","volume":"392","author":"Haber","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.01.018_bib42","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study","volume":"393","author":"Manthey","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2026.01.018_bib43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","volume":"80","author":"D\u00edaz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib44","article-title":"Primary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation","volume":"3","author":"Burton","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejso.2020.09.039","article-title":"Cholangiocarcinoma miscoding in hepatobiliary centres","volume":"47","author":"Selvadurai","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.01.018_bib46","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.01.018_bib47","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:55:41Z","timestamp":1789491341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826000589"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing epidemiology of primary liver cancer in the 21st century","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}